Gerald Wulf

14.1k total citations · 1 hit paper
152 papers, 5.3k citations indexed

About

Gerald Wulf is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Gerald Wulf has authored 152 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 46 papers in Hematology and 40 papers in Pathology and Forensic Medicine. Recurrent topics in Gerald Wulf's work include Lymphoma Diagnosis and Treatment (39 papers), CAR-T cell therapy research (27 papers) and Hematopoietic Stem Cell Transplantation (22 papers). Gerald Wulf is often cited by papers focused on Lymphoma Diagnosis and Treatment (39 papers), CAR-T cell therapy research (27 papers) and Hematopoietic Stem Cell Transplantation (22 papers). Gerald Wulf collaborates with scholars based in Germany, United States and Switzerland. Gerald Wulf's co-authors include Margaret A. Goodell, Malcolm K. Brenner, U. Göbel, Jed G. Nuchtern, Angela E. Foster, Thomas Jax, Wolfgang Engel, Karim Nayernia, Jae Ho Lee and Bjoern Chapuy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Gerald Wulf

136 papers receiving 5.2k citations

Hit Papers

A distinct “side populati... 2004 2026 2011 2018 2004 250 500 750 1000

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Gerald Wulf 2.9k 1.9k 849 819 771 152 5.3k
Kevin D. Bunting 3.0k 1.1× 3.0k 1.6× 811 1.0× 2.1k 2.6× 900 1.2× 111 6.5k
Norihiko Kawamata 2.2k 0.8× 1.4k 0.7× 588 0.7× 467 0.6× 610 0.8× 96 4.0k
Isidro Sánchez‐García 2.7k 1.0× 1.3k 0.7× 669 0.8× 461 0.6× 465 0.6× 115 4.4k
Cornelius Miething 3.0k 1.0× 1.5k 0.8× 740 0.9× 1.2k 1.5× 519 0.7× 68 5.1k
Bronislaw Pytowski 3.5k 1.2× 3.6k 1.9× 741 0.9× 790 1.0× 350 0.5× 61 6.5k
Marieke von Lindern 3.9k 1.4× 633 0.3× 699 0.8× 618 0.8× 884 1.1× 134 5.7k
D Delia 2.5k 0.9× 1.1k 0.6× 430 0.5× 1.1k 1.3× 793 1.0× 62 4.6k
Mireia Castillo-Martín 3.9k 1.4× 1.5k 0.8× 1.3k 1.5× 739 0.9× 204 0.3× 107 6.1k
Yangqiu Li 2.2k 0.8× 2.2k 1.1× 1.1k 1.2× 2.2k 2.7× 445 0.6× 294 5.5k
Dennis K. Watson 3.6k 1.2× 1.3k 0.7× 1.0k 1.2× 904 1.1× 375 0.5× 106 5.8k

Countries citing papers authored by Gerald Wulf

Since Specialization
Citations

This map shows the geographic impact of Gerald Wulf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Wulf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Wulf more than expected).

Fields of papers citing papers by Gerald Wulf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Wulf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Wulf. The network helps show where Gerald Wulf may publish in the future.

Co-authorship network of co-authors of Gerald Wulf

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald Wulf. A scholar is included among the top collaborators of Gerald Wulf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald Wulf. Gerald Wulf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Brünner, Franziska, Mathias Haenel, Igor Age Kos, et al.. (2025). Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Blood Advances. 10(7). 2186–2189.
3.
d’Amore, Francesco, Massimo Federico, Laurence de Leval, et al.. (2025). Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 36(6). 626–644.
4.
Gagelmann, Nico, Matthias Stelljes, Igor Wolfgang Blau, et al.. (2024). Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation. American Journal of Hematology. 99(8). 1540–1549. 2 indexed citations
5.
Wulf, Gerald, Ulrike Bacher, Mathias Rummel, et al.. (2024). Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe. Cancer Medicine. 13(10). e7289–e7289. 1 indexed citations
7.
Hasenkamp, Justin, et al.. (2023). Low incidence and morbidity of Epstein‐Barr virus reactivation following donor lymphocyte infusions. SHILAP Revista de lepidopterología. 4(2). 563–565.
9.
Schubert, Maria‐Luisa, Wolfgang Bethge, Francis Ayuk, et al.. (2023). Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study. Blood Advances. 7(20). 6191–6195. 9 indexed citations
10.
Seifert, Nicole, Deepak Vangala, Sabine Seidel, et al.. (2023). Treatment Strategies and Prognostic Factors in Secondary Central Nervous System Lymphoma: A Multicenter Study of 124 Patients. HemaSphere. 7(8). e926–e926. 2 indexed citations
11.
Evertz, Ruben, Miroslava Valentová, Friederike Braulke, et al.. (2022). Cardiovascular and Metabolic Determinants of Quality of Life in Patients with Cancer. ESC Heart Failure. 10(1). 167–176. 4 indexed citations
12.
Shumilov, Evgenii, Justin Hasenkamp, Nicole Schmidt, et al.. (2022). Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis. Hematological Oncology. 40(4). 763–776. 4 indexed citations
14.
Wulf, Gerald & Thomas Weber. (2019). Periphere T‑Zell-Lymphome. Der Onkologe. 25(10). 892–898.
15.
Venkataramani, Vivek, Thorsten R. Doeppner, Desiree Willkommen, et al.. (2018). Manganese causes neurotoxic iron accumulation via translational repression of amyloid precursor protein and H‐Ferritin. Journal of Neurochemistry. 147(6). 831–848. 65 indexed citations
16.
Doeppner, Thorsten R., Desiree Willkommen, Catherine M. Cahill, et al.. (2018). Manganese causes neurotoxic iron accumulation via translational repression of Amyloid Precursor Protein (APP) and H-Ferritin. PMC. 2 indexed citations
17.
Venkataramani, Vivek, Stefan Küffer, Kenneth Cheung, et al.. (2017). CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas. Clinical Cancer Research. 24(2). 460–473. 37 indexed citations
18.
Koch, Raphael, Thiha Aung, Daniel Vogel, et al.. (2015). Nuclear Trapping through Inhibition of Exosomal Export by Indomethacin Increases Cytostatic Efficacy of Doxorubicin and Pixantrone. Clinical Cancer Research. 22(2). 395–404. 109 indexed citations
19.
Hasenkamp, Justin, et al.. (2009). Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Annals of Hematology. 89(3). 283–289. 10 indexed citations
20.
Wulf, Gerald, Bjoern Chapuy, & Lorenz Trümper. (2006). [Mesenchymal stem cells from bone marrow. Phenotype, aspects of biology, and clinical perspectives].. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 101(5). 408–413. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026